New Eye Drop Treatment for Wet Age-Related Macular Degeneration
Part of Eyes & vision clinical trials.
This study tests a new experimental eye drop (EYC-0305) for wet AMD, a common cause of vision loss in older adults. The goal is to see if it can slow or prevent further damage to central vision.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 50 years or older
- You have been diagnosed with neovascular (wet) AMD—the type where abnormal blood vessels grow under the retina
- You can attend clinic visits and follow study procedures
- You don't have an allergy to the study drug or fluorescein dye (used for eye imaging)
- Your diabetes (if you have it) is well controlled with current treatment
- You have not had a stroke or heart attack in the past 6 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new injection medicine (AIV007) placed around the eye to treat wet age-related macular degeneration (a condition that damages central vision). You may qualify if you've been treated for this condition before and responded well to previous eye injections.
This study tests a new investigational drug called BETA-TT8 for people with wet age-related macular degeneration (wet AMD) who have already been treated with standard therapy (aflibercept). The goal is to see if this new treatment is safe and effective in improving vision.
This study tests a new eye drop medicine to see if it is safe and how the body handles it. It is for healthy adults only, not for treating a condition.
This study tests whether a new eye injection called ABP 938 works as well as or better than the current standard treatment (Eylea) for wet age-related macular degeneration—a condition that causes vision loss in the center of your sight. You would receive injections into your eye every month for a year.
This study tests whether a new eye drop medication (SCAI-005) can help people with wet age-related macular degeneration (a serious eye condition affecting central vision in older adults) who have already responded well to regular eye injections. The goal is to see if eye drops might work as an alternative treatment.
This trial tests a new medicine, EYE201, for people with wet age-related macular degeneration (AMD) that has not been treated before. The study will see if this drug can help improve vision and slow down vision loss.
Hear when a new Neovascular (Wet) Age-Related Macular Degeneration trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.